Cargando…

Outcome of patients aged 60‐75 years with newly diagnosed secondary acute myeloid leukemia: A single‐institution experience

A recent phase 3 trial showed that outcome of older patients with secondary acute myeloid leukemia (AML) may be improved by a liposomal encapsulation of cytarabine and daunorubicin (CPX‐351). This phase 3 study represents a unique example of prospective data in this rare subgroup providing basis for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertoli, Sarah, Tavitian, Suzanne, Bories, Pierre, Luquet, Isabelle, Delabesse, Eric, Comont, Thibault, Sarry, Audrey, Huguet, Françoise, Bérard, Emilie, Récher, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639188/ https://www.ncbi.nlm.nih.gov/pubmed/31173485 http://dx.doi.org/10.1002/cam4.2020

Ejemplares similares

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Vitamin C and D supplementation in acute myeloid leukemia
por: Mouchel, Pierre Luc, et al.
Publicado: (2023)

Improved outcome for AML patients over the years 2000–2014
por: Bertoli, Sarah, et al.
Publicado: (2017)

Genomic landscape of hyperleukocytic acute myeloid leukemia
por: Largeaud, Laetitia, et al.
Publicado: (2022)

Dexamethasone in hyperleukocytic acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2018)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response
por: Guenounou, Sarah, et al.
Publicado: (2016)

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies
por: Bertoli, Sarah, et al.
Publicado: (2016)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study
por: Bertoli, Sarah, et al.
Publicado: (2020)

Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
por: Vergez, François, et al.
Publicado: (2022)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients
por: Berger, Eloïse, et al.
Publicado: (2019)

Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
por: Dumas, Pierre-Yves, et al.
Publicado: (2020)

Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient
por: Beziat, Guillaume, et al.
Publicado: (2019)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Brachytherapy for uterine cervix-limited acute myeloid leukemia relapse
por: Beziat, Guillaume, et al.
Publicado: (2022)

CD36 Drives Metastasis and Relapse in Acute Myeloid Leukemia
por: Farge, Thomas, et al.
Publicado: (2023)

The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia
por: Liu, Chia‐Jen, et al.
Publicado: (2020)

Sodium orthovanadate inhibits growth of acute leukemia HL60 cells and HL60/A cells in vitro
por: Zhang, Lulu, et al.
Publicado: (2020)

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia
por: Bertoli, Sarah, et al.
Publicado: (2015)

CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
por: Touzet, Lucas, et al.
Publicado: (2019)

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
por: Récher, Christian, et al.
Publicado: (2021)

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
por: Bérard, Emilie, et al.
Publicado: (2022)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey
por: Bories, Pierre, et al.
Publicado: (2018)

Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL–Negative Myeloproliferative Neoplasms
por: Belliere, Julie, et al.
Publicado: (2020)

Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia: An Exhaustive Population-Based Study in France
por: Pajiep, Marie, et al.
Publicado: (2021)

Incidence and survival of hematological cancers among adults ages ≥75 years
por: Krok‐Schoen, Jessica L., et al.
Publicado: (2018)

Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
por: Malard, Florent, et al.
Publicado: (2021)

Activation of Vitamin D Receptor Pathway Enhances Differentiating Capacity in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations
por: Sabatier, Marie, et al.
Publicado: (2021)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
por: Tavitian, Suzanne, et al.
Publicado: (2015)

Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia
por: Larrue, Clément, et al.
Publicado: (2019)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Identification of survival-related alternative splicing signatures in acute myeloid leukemia
por: Zhang, Biyu, et al.
Publicado: (2021)

Determination of a radotinib dosage regimen based on dose–response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia
por: Noh, Hayeon, et al.
Publicado: (2018)

Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives
por: Wagstaff, Megan, et al.
Publicado: (2022)

A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Cost comparison of post-remission strategies in younger and older AML patients in France
por: Mounie, Michael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ebp29ucsd1pd67jotchmkmr0mg